TVGN: חוב כולל להון Tevogen Bio

The price history on the debt-to-equity chart for Tevogen Bio Holdings (TVGN) is 0.00. This biotech startup focuses on personalized T-cell therapy, assuming significant investment risks. The business relies on developing immune mechanisms to combat oncology and viruses. Personnel stability is supported by large-scale scientific research that attracts the industry's leading immunologists.

Tevogen Bio Holdings is facing an acute liquidity shortage due to costly clinical trials in the absence of revenue. This indicator measures the proportion of debt obligations within the equity structure, determining the financial leverage. An increase in this metric signals a critical rise in the credit load. It is essential for investors to monitor the sustainability of liabilities to eliminate the risk of bankruptcy. Analyzing the debt-to-equity ratio allows for an assessment of the business model's viability.